Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
100 hedge funds and large institutions have $64M invested in Sanofi Contingent Value Rights in 2018 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 16 closing their positions.
12% more capital invested
Capital invested by funds: $57.4M → $64M (+$6.63M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 105 → 100 (-5)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NGA
New Generation Advisors
Manchester,
Massachusetts
|
+$241K |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$161K |
| 3 |
PC
Permanens Capital
New York
|
+$45.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$10.8K |
| 5 |
Goldman Sachs
New York
|
+$2.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$76K |
| 2 |
First Eagle Investment Management
New York
|
-$56K |
| 3 |
BMO
Beck Mack & Oliver
New York
|
-$50.9K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$31.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$29K |
GCVRZ Hedge Fund Activity: Q1 2018 in Review
100 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2018, worth a combined $64M — up 12% from $57.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GCVRZ and 12 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 8 added.
The largest buyer was New Generation Advisors, adding an estimated $241K. The largest seller was B. Riley Financial, exiting entirely with an estimated $76K sold.
- 100 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2018, down from 105 in Q4 2017.
- Funds reported $64M of Sanofi Contingent Value Rights stock for Q1 2018, up 12% quarter-over-quarter.
- 12 funds opened new Sanofi Contingent Value Rights positions in Q1 2018 and 16 closed out, a net change of -4 holders.
- The largest Sanofi Contingent Value Rights buyer in Q1 2018 was New Generation Advisors, an estimated $241K added.
- The largest Sanofi Contingent Value Rights seller in Q1 2018 was B. Riley Financial, an estimated $76K sold.
Based on aggregated 13F filings for Q1 2018.